Ra Pharmctl Inc (NASDAQ:RARX) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 617,125 shares, a drop of 31.1% from the October 13th total of 895,531 shares. Based on an average daily volume of 180,782 shares, the short-interest ratio is currently 3.4 days. Approximately 6.7% of the company’s stock are sold short.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in shares of Ra Pharmctl by 166.2% during the third quarter. Wells Fargo & Company MN now owns 23,842 shares of the company’s stock valued at $348,000 after acquiring an additional 14,885 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Ra Pharmctl during the third quarter valued at approximately $4,664,000. JPMorgan Chase & Co. increased its position in shares of Ra Pharmctl by 28.2% during the third quarter. JPMorgan Chase & Co. now owns 256,300 shares of the company’s stock valued at $3,742,000 after acquiring an additional 56,400 shares in the last quarter. Candriam Luxembourg S.C.A. increased its position in shares of Ra Pharmctl by 43.2% during the third quarter. Candriam Luxembourg S.C.A. now owns 116,000 shares of the company’s stock valued at $1,694,000 after acquiring an additional 35,000 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Ra Pharmctl by 26.1% during the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock valued at $390,000 after acquiring an additional 4,300 shares in the last quarter. 66.74% of the stock is owned by institutional investors.

Ra Pharmctl (NASDAQ RARX) opened at $14.11 on Tuesday. Ra Pharmctl has a one year low of $11.20 and a one year high of $27.84.

Ra Pharmctl (NASDAQ:RARX) last announced its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06). equities research analysts forecast that Ra Pharmctl will post -2.54 earnings per share for the current year.

A number of brokerages have weighed in on RARX. Zacks Investment Research raised shares of Ra Pharmctl from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Jefferies Group LLC set a $25.00 target price on shares of Ra Pharmctl and gave the company a “buy” rating in a research note on Friday, August 25th. Royal Bank Of Canada began coverage on shares of Ra Pharmctl in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 target price for the company. Finally, Credit Suisse Group raised their target price on shares of Ra Pharmctl from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $24.67.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/14/ra-pharmctl-inc-rarx-sees-significant-drop-in-short-interest.html.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.